Sumitomo Dainippon Pharma has completed the acquisition of US specialty company Tolero for up to $780m in a move that boosts the mid-sized Japanese firm's presence in oncology ahead of a looming major patent expiry for its top-selling product.
Sumitomo Dainippon Pharma Co. Ltd. (SDP) has paid $200m upfront for Lehi, Utah-based Tolero Pharmaceuticals Inc., and agreed further milestone payments of up to $430m related to the progress of Tolero's pipeline, plus up to $150m in post-launch commercial milestones based on net sales of commercialized Tolero-sourced products.
The deal, first announced in late December, immediately gives DSP a portfolio of six development-stage molecules in oncology, including hematologic...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
